Eli Lilly
LLY
$819.36
Share price
0.90%
Change (1 day)
-7.24%
Change (1 year)
Categories
With over 33,000 employees worldwide, production plants in 13 countries and annual sales of over $22 billion worldwide, Eli Lilly and Company is one of the largest pharmaceutical companies in the world. It was founded in Indianapolis in 1876 by the pharmacologist, officer and entrepreneur Eli Lilly.
Eli Lilly (LLY) Fails to deliver data
Key failure to deliver metrics for Eli Lilly:
- Last SEC data release: 2025-05-14
- Last 15 days FTD volume: $8.13 M
- Last 3 months FTD volume: $33.35 M
- Last year FTD volume: $33.35 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Eli Lilly (LLY) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Eli Lilly (LLY) - since 2013
Volume in USD (price x number of shares), data since 2013Eli Lilly (LLY) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | $61.55 M | -69.41% |
| 2024 | $0.20 B | 88.85% |
| 2023 | $0.10 B | -66.81% |
| 2022 | $0.32 B | 85.59% |
| 2021 | $0.17 B | 58.21% |
| 2020 | $0.10 B | -92.8% |
| 2019 | $1.51 B | 610.41% |
| 2018 | $0.21 B | 266.45% |
| 2017 | $58.34 M | -45.27% |
| 2016 | $0.10 B | -15.04% |
| 2015 | $0.12 B | -40.32% |
| 2014 | $0.21 B | 796.57% |
| 2013 | $23.45 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Bristol-Myers Squibb BMY | $39.5 M | $0.27 B | 🇺🇸 USA |
 Merck MRK | $45.1 M | $0.17 B | 🇺🇸 USA |
 Johnson & Johnson JNJ | $12.85 M | $0.20 B | 🇺🇸 USA |
 Pfizer PFE | $35.84 M | $0.35 B | 🇺🇸 USA |
 Sanofi SNY | $24.53 M | $42.3 M | 🇫🇷 France |
 GlaxoSmithKline GSK | $0.16 B | $0.31 B | 🇬🇧 UK |
 AbbVie ABBV | $36.08 M | $0.23 B | 🇺🇸 USA |
 Amgen AMGN | $0.16 B | $0.32 B | 🇺🇸 USA |
 Novartis NVS | $50.39 M | $0.16 B | 🇨🇭 Switzerland |
 AstraZeneca AZN | $38.37 M | $0.14 B | 🇬🇧 UK |